Replies to post #169064 on Biotech Values

[DewDiligence]

GlobeImmune is again trying to IPO:

http://www.renaissancecapital.com/ipohome/news/pancreatic-cancer-biotech-globeimmune-refiles-for-a-$35-million-ipo-18364.html

GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, filed on Monday with the SEC to raise up to $35 million in an initial public offering. The company previously tried to go public in September 2012 but postponed in October 2012 and withdrew in October 2013. The Louisville, CO-based company, which was founded in 1995 and booked $23 million in collaboration revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol GBIM. Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.

I agree with ‘genisi’ that GlobeImmune’s HCV program is obsolete. (A 2010 PR on the program is in #msg-49095438.)